Transcatheter Aortic Valve Replacement in Pure Native Aortic Valve Regurgitation: Challenging Pathology Awaiting Specialized Devices

Abstract

Patients with aortic incompetence frequently present with anatomical and pathological challenges such as elliptical dilated annulus, dilated aortic root, dilated ascending aorta, and with no calcification in the aortic cusps or annulus. Patients are commonly in graver clinical condition as a result of a long silent clinical course before overt congestive heart failure. All of the above make transcatheter therapies for native aortic valve regurgitation more challenging with poorer outcomes, escalating the risk of insufficient anchoring, prosthesis migration, and residual paravalvular leak compared with current transcatheter aortic valve replacement (TAVR) outcomes for aortic stenosis. There is a need for specialized TAVR devices to address this complex pathology. Surgical aortic valve replacement is the current treatment option and the gold standard for patients with aortic incompetence (AR). Currently, the specific off-label indication for TAVR in pure native AR could be a feasible and reasonable option, as a compassionate treatment is limited to inoperable patients and agreed on by the heart team.

Keywords

pure native aortic incompetence - TAVR for aortic incompetence - surgical aortic valve replacement

Publikationsverlauf

Eingereicht: 23. März 2020

Angenommen: 11. November 2020

Artikel online veröffentlicht:
07. Oktober 2021

• Reference

• 1 Leon MB, Smith CR, Mack M. et al; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363 (17) 1597-1607
• 2 Smith CR, Leon MB, Mack MJ. et al; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011; 364 (23) 2187-2198
• 3 Leon MB, Smith CR, Mack MJ. et al; PARTNER 2 Investigators. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016; 374 (17) 1609-1620
• 4 Nishimura RA, Otto CM, Bonow RO. et al; American College of Cardiology, American College of Cardiology/American Heart Association, American Heart Association. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg 2014; 148 (01) e1-e132
• 5 Gummert JF, Funkat AK, Beckmann A. et al. Cardiac surgery in Germany during 2010: a report on behalf of the German Society for Thoracic and Cardiovascular Surgery. Thorac Cardiovasc Surg 2011; 59 (05) 259-267
• 6 Roy D, Sharma R, Brecker SJ. Native aortic valve regurgitation: transcatheter therapeutic options. EuroIntervention 2013; 9 (suppl): S55-S62
• 7 Kamath AR, Varadarajan P, Turk R. et al. Survival in patients with severe aortic regurgitation and severe left ventricular dysfunction is improved by aortic valve replacement: results from a cohort of 166 patients with an ejection fraction < or =35%. Circulation 2009; 120 (11, suppl): S134-S138
• 8 Akinseye OA, Pathak A, Ibebuogu UN. Aortic valve regurgitation: a comprehensive review. Curr Probl Cardiol 2018; 43 (08) 315-334
• 9 Olszowska M. Pathogenesis and pathophysiology of aortic valve stenosis in adults. Pol Arch Med Wewn 2011; 121 (11) 409-413
• 10 Maurer G. Aortic regurgitation. Heart 2006; 92 (07) 994-1000
• 11 Sawaya FJ, Deutsch MA, Seiffert M. et al. Safety and efficacy of transcatheter aortic valve replacement in the treatment of pure aortic regurgitation in native valves and failing surgical bioprostheses: results from an international registry study. JACC Cardiovasc Interv 2017; 10 (10) 1048-1056
• 12 Shang EK, Nathan DP, Sprinkle SR. et al. Peak wall stress predicts expansion rate in descending thoracic aortic aneurysms. Ann Thorac Surg 2013; 95 (02) 593-598
• 13 Roy DA, Schaefer U, Guetta V. et al. Transcatheter aortic valve implantation for pure severe native aortic valve regurgitation. J Am Coll Cardiol 2013; 61 (15) 1577-1584
• 14 Testa L, Latib A, Rossi ML. et al. CoreValve implantation for severe aortic regurgitation: a multicentre registry. EuroIntervention 2014; 10 (06) 739-745
• 15 Frerker C, Schewel J, Schewel D. et al. Expansion of the indication of transcatheter aortic valve implantation--feasibility and outcome in “off-label” patients compared with “on-label” patients. J Invasive Cardiol 2015; 27 (05) 229-236
• 16 Yoon SH, Schmidt T, Bleiziffer S. et al. Transcatheter aortic valve replacement in pure native aortic valve regurgitation. J Am Coll Cardiol 2017; 70 (22) 2752-2763
• 17 Praz F, Windecker S, Huber C, Carrel T, Wenaweser P. Expanding indications of transcatheter heart valve interventions. JACC Cardiovasc Interv 2015; 8 (14) 1777-1796
• 18 Tofield A. Feasibility trial reports deployment of new device for TAVI in aortic insufficiency. Eur Heart J 2013; 34 (33) 2578
• 19 Barbanti M, Ye J, Pasupati S, El-Gamel A, Webb JG. The Helio transcatheter aortic dock for patients with aortic regurgitation. EuroIntervention 2013; 9 (suppl): S91-S94
• 20 Schlingloff F, Schäfer U, Frerker C, Schmoeckel M, Bader R. Transcatheter aortic valve implantation of a second-generation valve for pure aortic regurgitation: procedural outcome, haemodynamic data and follow-up. Interact Cardiovasc Thorac Surg 2014; 19 (03) 388-393
• 21 Dvir D, Webb JG, Bleiziffer S. et al; Valve-in-Valve International Data Registry Investigators. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA 2014; 312 (02) 162-170